In the U.S., we market UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta®, CIMERLI® (ranibizumab-eqrn), a biosimilar of Lucentis® and YUSIMRY™ (adalimumab-aqvh), a biosimilar of Humira®, and plan to launch our next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi) in Q1 2024.
Our strategy is to invest cash flows from our commercial biosimilar business to build an immuno-oncology franchise that will be synergistic with our proven commercial capabilities in oncology.
The foundational therapy in our immuno-oncology pipeline is LOQTORZI, a next-generation PD-1 inhibitor. Through our acquisition of Surface Oncology, Coherus’ immuno-oncology pipeline includes casdozokitug, a novel first-in-class anti-IL-27 antibody currently being evaluated in Phase 1/2 clinical trials in lung and liver cancer. CHS-114 is a highly selective, competitively positioned anti-CCR8 antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.
Our earlier-stage immuno-oncology pipeline includes CHS-006, a TIGIT-targeted antibody, being evaluated in a Phase 1/2 trial in combination with toripalimab in patients with advanced solid tumors. Coherus is discovering and developing additional immuno-therapies for cancer targeting novel pathways such as ILT4 and others.
